Use of a rare disease patient registry in long-term post-authorisation drug studies
Release Date:
Dr. Diana Bilton joins The Lancet Respiratory Medicine to discuss how the use of rare disease patient registries helps with long term drug studies after drug authorisation.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Use of a rare disease patient registry in long-term post-authorisation drug studies